Tracked shipping to the Netherlands for just € 7. Prices include 9% BTW and new EU € 3 customs duty. No hidden fees. 

Ship to
Netherlands
0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

Select your country

Americas

Europe

Rest of the world

portada 31st hemophilia symposium: hamburg 2000
Type
Physical Book
Publisher
Year
2001
Language
English
Pages
287
Format
Paperback
Dimensions
23.4 x 15.6 x 1.7 cm
Weight
0.45 kg.
ISBN
3540421319
ISBN13
9783540421313

31st hemophilia symposium: hamburg 2000

I. Scharrer (Illustrated by) · W. Schramm (Illustrated by) · Springer · Paperback

31st hemophilia symposium: hamburg 2000 - Scharrer, I. ; Schramm, W.

Cheaper New Book Imported to Netherlands
Delivery: 10 Aug - 13 Aug Shipping: 13 to 15 business days.
110,63 €
Faster New Book Imported to Netherlands
Delivery: 29 Jul - 31 Jul Shipping: 5 to 6 business days.
135,28 €
Import costs and 9% BTW included in the price ✅
110,63 €

Synopsis "31st hemophilia symposium: hamburg 2000"

Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat- ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re- quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat- ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.

Customers reviews

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews